Shen, Zhewei
Halberg, Anna
Fong, Jia Yi
Guo, Jingyu
Song, Gavin
Louie, Brent
Luedtke, Gregory R.
Visuthikraisee, Viwat
Protter, Andrew A.
Koh, Xiaoying
Baik, Taegon
Lum, Pek Yee
Article History
Received: 21 April 2022
Accepted: 7 October 2022
First Online: 5 November 2022
Competing interests
: SARS-CoV-2 studies were conducted at Institut Pasteur Korea (South Korea) and funded by Arum Therapeutics and Auransa Inc. HCoV-229E and HCoV-OC43 studies were conducted and funded by Experimental Drug Development Centre (Singapore). Auransa Inc. sourced all compounds used in in vitro testing. Shen Z., Guo J., Song G., Louie B., Halberg A., Luedtke G.R., Protter A., Visuthikraisee V., and Lum P.Y. are employees of Auransa Inc. and hold equity in the company. Baik T. is an employee of Arum therapeutics and holds equity in the company. Fong J.Y. and Koh X. are employees of Experimental Drug Development Centre (Singapore) and have no conflict of interest.